319 related articles for article (PubMed ID: 36135095)
1. Immunogenic Cell Death Role in Urothelial Cancer Therapy.
Yadollahvandmiandoab R; Jalalizadeh M; Buosi K; Garcia-Perdomo HA; Reis LO
Curr Oncol; 2022 Sep; 29(9):6700-6713. PubMed ID: 36135095
[TBL] [Abstract][Full Text] [Related]
2. The Ability of Clinically Relevant Chemotherapeutics to Induce Immunogenic Cell Death in Squamous Cell Carcinoma.
He Z; Jing X; Dai X; Bao L; Yang X; Xiong Y; Li M
Front Biosci (Landmark Ed); 2024 Apr; 29(4):158. PubMed ID: 38682206
[TBL] [Abstract][Full Text] [Related]
3. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.
Inoue H; Tani K
Cell Death Differ; 2014 Jan; 21(1):39-49. PubMed ID: 23832118
[TBL] [Abstract][Full Text] [Related]
4. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
[TBL] [Abstract][Full Text] [Related]
5. Targeting immunogenic cell death in cancer.
Ahmed A; Tait SWG
Mol Oncol; 2020 Dec; 14(12):2994-3006. PubMed ID: 33179413
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases.
Eek Mariampillai A; Hauge S; Kongsrud K; Syljuåsen RG
Front Immunol; 2023; 14():1138920. PubMed ID: 37346039
[TBL] [Abstract][Full Text] [Related]
7. Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells.
D'Eliseo D; Manzi L; Velotti F
Cell Stress Chaperones; 2013 Nov; 18(6):801-8. PubMed ID: 23580156
[TBL] [Abstract][Full Text] [Related]
8. Gold standard assessment of immunogenic cell death induced by photodynamic therapy: From in vitro to tumor mouse models and anti-cancer vaccination strategies.
Mishchenko TA; Balalaeva IV; Turubanova VD; Saviuk MO; Shilyagina NY; Krysko O; Vedunova MV; Krysko DV
Methods Cell Biol; 2024; 183():203-264. PubMed ID: 38548413
[TBL] [Abstract][Full Text] [Related]
9. Many faces of DAMPs in cancer therapy.
Krysko O; Løve Aaes T; Bachert C; Vandenabeele P; Krysko DV
Cell Death Dis; 2013 May; 4(5):e631. PubMed ID: 23681226
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic cell death and DAMPs in cancer therapy.
Krysko DV; Garg AD; Kaczmarek A; Krysko O; Agostinis P; Vandenabeele P
Nat Rev Cancer; 2012 Dec; 12(12):860-75. PubMed ID: 23151605
[TBL] [Abstract][Full Text] [Related]
11. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
Garg AD; Elsen S; Krysko DV; Vandenabeele P; de Witte P; Agostinis P
Oncotarget; 2015 Sep; 6(29):26841-60. PubMed ID: 26314964
[TBL] [Abstract][Full Text] [Related]
12. 4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.
Hufnagel S; Xu H; Colemam MF; Valdes SA; Liu KA; Hursting SD; Cui Z
Cancer Chemother Pharmacol; 2022 Jan; 89(1):59-69. PubMed ID: 34698902
[TBL] [Abstract][Full Text] [Related]
13. Microbes mediated immunogenic cell death in cancer immunotherapy.
Huang J; Duan F; Xie C; Xu J; Zhang Y; Wang Y; Tang YP; Leung EL
Immunol Rev; 2024 Jan; 321(1):128-142. PubMed ID: 37553793
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies.
Wang Q; Ju X; Wang J; Fan Y; Ren M; Zhang H
Cancer Lett; 2018 Dec; 438():17-23. PubMed ID: 30217563
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-mediated immunogenic cell death for cancer immunotherapy.
Qi H; Li Y; Geng Y; Wan X; Cai X
Int J Pharm; 2024 May; 656():124045. PubMed ID: 38561134
[TBL] [Abstract][Full Text] [Related]
16. Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers.
Chiaravalli M; Spring A; Agostini A; Piro G; Carbone C; Tortora G
Cells; 2022 Sep; 11(19):. PubMed ID: 36230995
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives.
Aria H; Rezaei M
Biomed Pharmacother; 2023 May; 161():114503. PubMed ID: 36921539
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
García-Perdomo HA; Sánchez AL; Spiess PE
Urol Oncol; 2022 Sep; 40(9):409.e1-409.e8. PubMed ID: 35232680
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic cell death in cancer therapy: Present and emerging inducers.
Zhou J; Wang G; Chen Y; Wang H; Hua Y; Cai Z
J Cell Mol Med; 2019 Aug; 23(8):4854-4865. PubMed ID: 31210425
[TBL] [Abstract][Full Text] [Related]
20. Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy.
Yu S; Xiao H; Ma L; Zhang J; Zhang J
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188946. PubMed ID: 37385565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
